$BIAFJun 18, 2026, 5:16 PMAI processed
BIAF $3.2M registered offering — 4.0M shares or pre-funded warrants at $0.80
AI Summary
BioAffinity (NASDAQ: BIAF / BIAFW) announced a registered public offering of 4,000,000 shares of common stock (or pre‐funded warrants in lieu) at $0.80 per share (pre‐funded warrants at $0.793) for aggregate gross proceeds of $3.2 million, with WallachBeth Capital as sole placement agent. The company says the offering is expected to close on or about June 18, 2026, so dilution is delayed until closing; issued pre‐funded warrants will be immediately exercisable into common shares. Timing: Warrant exercises are already completed, so dilution is already in effect.
Positives
- Company to receive approximately $3.2M in gross proceeds
- Pre‑funded warrant path allows buyers to acquire shares despite ownership limits
Negatives
- Up to 4,000,000 new shares (or equivalent via pre‑funded warrants) will be issued, increasing outstanding share count
- Pre‑funded warrants are immediately exercisable, so conversion can add share supply at or shortly after closing
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: already triggered
Dilution status
live_now
Dilution timing
Dilution status: Immediate
Trigger type
already_triggered